The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous busulfan, cyclophosphamide and etoposide (i.v. Bu/Cy/E) as a conditioning regimen prior to autologous hematopoietic stem cell transplantation in patients with non-Hodgkin's lymphoma (NHL). Sixty-four patients with relapsed/ refractory (n ¼ 36) or high-risk (n ¼ 28) lymphoma were enrolled. The high-dose chemotherapy consisted of i.v. Bu (0.8 mg kg À1 i.v. q 6 h from day À7 to day À5), Cy (50 mg kg À1 i.v. on day À3 and day À2) and E (400 mg m À2 i.v. on day À5 and day À4). The median age was 43 (range 18-65) years, and 39 patients were male. Diffuse large B-cell lymphoma (40.6%) was the most common histological subtype. All evaluable patients achieved an engraftment of neutrophils (median, day 12) and platelets (median, day 13). Hepatic veno-occlusive disease was observed in four patients (three mild, one moderate grade), and two patients (3.1%) died from treatment-related complications. At a median follow-up of 16.4 months, 15 patients (23.4%) exhibited a relapse or progression, while 13 patients (20.3%) had died of disease. The estimated 3-year overall and progression-free survival for all patients was 72.1 and 70.1%, respectively. In conclusion, the conditioning regimen of i.v. Bu/Cy/E was well tolerated and seemed to be effective in patients with aggressive NHL.
Introduction
High-dose chemotherapy followed by autologous stem cell rescue is the current standard of care after primary-therapy failure for patients with aggressive non-Hodgkin's lymphoma (NHL). 1 Studies conducted in the 1980s demonstrated that patients with at least partial remission of a relapsed disease after submyeloablative chemotherapy have a 35-50% long-term survival rate with various conditioning regimens. [2] [3] [4] [5] [6] In a landmark randomized trial, 3 patients with a sensitive relapse achieved a 53% long-term survival with high-dose chemotherapy versus a 32% long-term survival with continued nonmyeloablative chemotherapy (P ¼ 0.038). Furthermore, autologous stem cell transplantation (ASCT) as a consolidation treatment has exhibited superior survival compared to conventional chemotherapy for young patients with high-risk NHL in several clinical trials. 7, 8 While carmustine (BCNU) and total body irradiationbased regimens are commonly used, the relative effectiveness of different preparative regimens has been difficult to determine, as most previous studies have been small with few meaningful comparisons between regimens. Busulfan (Bu)-based preparative regimens, which are commonly used with allogeneic SCT, 9 have also been studied with ASCT for lymphomas. 10, 11 As a result, several studies have reported a long-term survival of 45% after ASCT for patients with aggressive NHL when using a busulfan/ cyclophosphamide/etoposide (Bu/Cy/E) preparative, previously developed for allogeneic SCT. [10] [11] [12] However, the difficulty in predicting and assessing the dose delivered with the oral administration of high-dose Bu in preparative regimens for SCT results in a significant risk of lethal pulmonary or hepatic toxicity due to inadvertent overdosing, 13 or else the potential of graft failure 14 or a persistent malignant disease after transplantation due to under-dosing. 15 After the introduction of a parenteral formula of Bu, several studies have noted that i.v. Bu as part of a preparative regimen is effective and can reduce venoocclusive disease (VOD) and early treatment mortality with allogeneic hematopoietic SCT. [16] [17] [18] However, very few studies have focused on the effectiveness and safety of i.v. Bu in an ASCT setting. Accordingly, the current study attempted to evaluate the efficacy and toxicity of the combination of i.v. Bu, Cy and E as a conditioning regimen prior to ASCT in patients with NHL.
Materials and methods

Patient enrollment
Patients with a high-intermediate/high-risk international prognostic index at diagnosis or with salvage chemotherapy-sensitive relapse/refractory NHL were considered eligible for ASCT. Other inclusion criteria were age p65 years; Eastern Cooperative Oncology Group performance status p2; and normal cardiac, pulmonary, renal and hepatic function tests. All patients gave informed consent for high-dose chemotherapy followed by ASCT and written consent for the use of their records for research.
Hematopoietic stem cell mobilization and collection All patients underwent transplantation with peripheral blood hematopoietic stem cells mobilized with a granulocyte colony-stimulating factor alone (n ¼ 24, 37.5%) or chemotherapy plus the granulocyte colony-stimulating factor (n ¼ 40, 62.5%). The hematopoietic stem cells were collected from all patients using high-volume leukapheresis through a large-bore central venous catheter, with a target of more than 2 Â 10 6 kg À1 of CD34 þ cells.
Conditioning regimen
The conditioning regimen before the ASCT consisted of i.v. Bu (Busulfex, Jeil-Kirin Pharm Inc., Seoul, Korea; 0.8 mg kg À1 i.v. q 6 h from day À7 to day À5), Cy (50 mg kg À1 i.v. on day À3 and day À2) and E (400 mg m À2 i.v. on day À5 and day À4). The hematopoietic stem cells were infused on day 0. The Busulfex infusions were admixed as per the package insert guidelines to a final concentration of 0.54 mg ml À1 . The chemotherapy doses were based on the actual body weight or ideal body weight, whichever was less; however, if the actual body weight exceeded the ideal body weight by 20%, then the ideal body weight þ 10% was used for the dosage calculations.
Supportive care
All patients received a seizure prophylaxis with phenytoin at a dose of 1 g per os (load) on day 1 prior to the first dose of Bu, followed by 300 mg per os daily for 4 days. The serum phenytoin levels were not monitored. The uroepithelial prophylaxis for Cy administration consisted of hyperhydration and mesna. The granulocyte colony-stimulating factor was given daily at a dose of 5 mg kg À1 following the transplantation until the neutrophil count reached 5 Â 10 9 l
À1
. The antiemetics, blood component, antibacterial and antifungal antibiotics, and other supportive care measures were all used according to the respective guidelines at each institution.
Definition and evaluation criteria
The day of the stem cell infusion was defined as day 0. Myeloid engraftment was defined as the first day of 3 consecutive days when the absolute neutrophil count was X0.5 Â 10 9 l
À1
, while platelet engraftment was defined as the time taken to achieve platelets X20 Â 10 9 l À1 without requiring a transfusion. The patient response was evaluated 1 month after the transplantation and thereafter every 3 months during the follow-up according to the NHL response criteria, 19 plus the toxicity was evaluated and graded according to the National Cancer Institute Common Toxicity Criteria version 3.0 grading system. Cytomegalovirus antigenemia was also monitored after transplantation, and hepatic VOD defined according to the clinical criteria devised by McDonald et al. 20 
Statistical analysis
The principal end points in the present study included overall survival (OS) and progression-free survival (PFS). OS was measured from the transplantation day until the date of death or last follow-up, while PFS was calculated from the transplantation day until disease progression, relapse or death from any cause. The survival curves were plotted using the Kaplan-Meier method, and the statistical data obtained using an SPSS software package (SPSS 11.0 Inc., Chicago, IL, USA).
Results
Patient characteristics
Sixty-four patients with aggressive NHL were enrolled between May 2004 and September 2006 at eight medical centers in Korea, and the patient characteristics are summarized in Table 1 . The median age was 43 (range 18-65) years, and 39 patients were male. Diffuse large B-cell lymphoma (40.6%) was the most common histological subtype. Thirty-four patients (53.1%) were classified as high intermediate or high risk according to the international prognostic index scoring system at the time of diagnosis. Thirty-eight patients (59.4%) had received at least two chemotherapy regimens before transplantation, while 36 patients (56.2%) had a relapsed or refractory disease at the time of transplantation.
Engraftment, toxicity and transplant-related mortality The engraftment and toxicity results are summarized in Table 2 . The median dose of CD34 þ and mononuclear cells transplanted was 6.0 Â 10 6 and 8.2 Â 10 8 kg
À1
, respectively. Since two patients died before day 30, 62 patients were evaluated for hematopoietic recovery. All evaluable patients achieved an engraftment of neutrophils (median, day 12) and platelets (median, day 13), although the platelet engraftment was delayed in the case of three patients (days 62, 106 and 139). The most common nonhematologic toxicity was mucositis, which occurred with a grade 1/2 intensity in 36 patients (56.3%). Hepatic VOD was observed in four patients (three mild and one moderate grade), plus one patient required treatment. Although bacteremia was documented in eight patients (12.5%), all were successfully treated with antibiotics. One patient with refractory peripheral T-cell lymphoma, who received alemtuzumab and cytotoxic chemotherapy as a salvage treatment, developed cytomegalovirus retinitis after transplantation. Two patients (3.1%) died within 30 days of transplantation from treatment-related complications. One patient died from bleeding and another from sudden cardiogenic shock.
Response and survival Fifty-one patients (79.7%) achieved a complete response 1 month after ASCT, while two patients showed progressive disease. Among 25 patients with NHL in a partial response at transplantation, 12 patients (48.0%) converted partial response to a complete response after transplantation. At a median follow-up of 16.4 months (range 0.4-37.1), 15 patients (23.4%) exhibited a relapse or progression, while 13 patients (20.3%) had died of disease. The estimated 3-year OS and PFS for all patients was 72.176.5 and 70.176.1%, respectively (Figure 1 ). The survival of the patients with high-risk NHL showed a superior trend to that of the patients with relapsed or refractory NHL (estimated 3-year OS; 76.9710.1 versus 69.277.7%, P-value ¼ 0.2386: estimated 3-year PFS; 76.078.8 versus 65.678.1%, P-value ¼ 0.2721) (Figure 2) , while the survivals between the B-cell NHL and T-cell NHL were not different (estimated 3-year OS; 70.279.9 versus 74.577.8%). In the multivariate analysis, including sex, age, pathologic subtype and status at transplantation, no statistically significant factor was observed (data not shown).
Discussion
In the current study, the combination chemotherapy of i.v. Bu/Cy/E as a conditioning regimen prior to ASCT produced active antitumor activity and a safe toxicity profile in patients with aggressive NHL. The estimated 3-year OS of 69.2% for the patients with relapsed/ refractory NHL and 76.9% for the patients with high-risk NHL following treatment with the study regimen were comparable to previous results reported for other conditioning regimens, although the median follow-up was short in the current study. [3] [4] [5] [6] [7] [8] For example, the commonly used conditioning regimen of BCNU, etoposide, cytarabine, cyclophosphamide and mesna demonstrated a 5-year OS of 53% for patients with chemotherapy-sensitive NHL in relapse in a randomized trial. 3 Meanwhile, Gulati et al.
5
reported that a hyperfractionated total body irradiation, E and Cy combination regimen produced a long-term diseasefree survival of 57% in patients with refractory and resistant NHL. However, a recent report by Bhatia et al. 21 for the Bone Marrow Transplant Survivor Study documented a significantly increased late nonrelapse mortality after ASCT for hematologic malignancies with BCNU-based regimens that was not observed with Bu-or total body irradiation-based regimens, thereby supporting the search for safer and equally effective preparative regimens.
Since Bu-based conditioning regimens have been extensively utilized in autologous and allogeneic SCT for a variety of lymphohematopoietic disorders, several studies have also been performed for NHL. [10] [11] [12] 22 Copelan et al. ) regimen was effective (3-year OS, 63%) and well tolerated in 53 patients with Hodgkin's disease or NHL. However, a relative high incidence (2.9-5.8%) of severe VOD, which is life threatening, was also observed in their studies. Furthermore, since the pharmacokinetic profile of orally administered Bu demonstrates wide interpatient and intrapatient variability due to age-related differences, alterations in absorption, circadian variations and drugdrug interactions, the oral administration of high-dose Bu for SCT can cause a significant risk of hepatic toxicity. [23] [24] [25] Although attempts to develop an i.v. preparation of Bu were initially limited due to the drug's poor aqueous solubility, several formulations have since been investigated, including a formulation that uses dimethyl acetamide and polyethylene glycol (i.v. Busulfex). After the introduction of i.v. Bu, several studies have demonstrated a lower incidence rate of VOD with a Bu/Cy preparative Figure 2 Overall (a) and progression-free survival (b) curves according to status at transplantation (P-value ¼ not significant).
regimen due to its dose assurance with predictable pharmacokinetics. 16, 17 A recent historically controlled study by Aggarwal et al. 26 also reported that the substitution of i.v. Bu for oral Bu in a Bu/Cy/E conditioning regimen improved the outcomes for patients with intermediate-and high-risk aggressive NHL who underwent ASCT, with the suggestion that this was primarily due to a decreased Bu-associated regimen-related mortality. In the present study, as the total dose of i.v. Bu was reduced (0.8 mg kg À1 every 6 h for 3 days), only one patient (1.6%) experienced moderate VOD, while two patients (3.1%) died from treatment-related mortality.
In conclusion, a conditioning regimen of i.v. Bu/Cy/E was found to be well tolerated and seemed to be effective in patients with aggressive NHL. Accordingly, this regimen can be regarded as an important treatment option for ASCT in the case of NHL.
